Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016

  • ID: 3783276
  • Report
  • 67 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • Eli Lilly and Company
  • Milo Biotechnology LLC
  • Pfizer Inc.
  • Scholar Rock, Inc.
  • MORE
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016

Summary

‘Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016’, provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics.

The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF-8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • Eli Lilly and Company
  • Milo Biotechnology LLC
  • Pfizer Inc.
  • Scholar Rock, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Growth/Differentiation Factor 8 (Myostatin or GDF-8) Overview

Therapeutics Development

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Stage of Development

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Therapy Area

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Indication

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Companies

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Companies Involved in Therapeutics Development

Acceleron Pharma, Inc.

Atara Biotherapeutics, Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

Milo Biotechnology LLC

Pfizer Inc.

Regeneron Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Scholar Rock, Inc.

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Drug Profiles

AAV1-Foliistatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AAV9-Follistatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACE-083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACE-2494 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACE-2798 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

domagrozumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landogrozumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

luspatercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRK-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trevogrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Dormant Projects

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Discontinued Products

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Featured News & Press Releases

May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association

May 09, 2016: Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients

Dec 07, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

Dec 05, 2015: Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 01, 2015: Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting

Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting

Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event

Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-083 at the 20th International Annual Congress of the World Muscle Society

Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-2494 at the 20th International Annual Congress of the World Muscle Society

Sep 23, 2015: Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program

Jun 12, 2015: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

Jun 09, 2015: Acceleron Pharma to Host Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association

May 21, 2015: Acceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology Association

May 18, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

May 02, 2015: Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Acceleron Pharma, Inc., H1 2016

Pipeline by Atara Biotherapeutics, Inc., H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by Milo Biotechnology LLC, H1 2016

Pipeline by Pfizer Inc., H1 2016

Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

Pipeline by Sarepta Therapeutics, Inc., H1 2016

Pipeline by Scholar Rock, Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • Eli Lilly and Company
  • Milo Biotechnology LLC
  • Pfizer Inc.
  • Scholar Rock, Inc.
  • MORE
Growth/Differentiation Factor 8 (Myostatin or GDF-8) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.Our latest report GrowthDifferentiation Factor 8 – Pipeline Review, H1 2016, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth/Differentiation Factor 8 (Myostatin or GDF-8) Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGFß) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 7 respectively.

Furthermore, this report also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Acceleron Pharma, Inc.
Atara Biotherapeutics, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Milo Biotechnology LLC
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Scholar Rock, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll